All Stories

  1. Factors associated with resistance to SARS-CoV-2 infection discovered using large-scale medical record data and machine learning
  2. Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance
  3. Users beware! Biological variation in complete blood counts over short time intervals
  4. Building Leadership Capacity for Mission Execution in a Large Academic Department of Medicine
  5. Joint Holographic Detection and Reconstruction
  6. An Optical Model of Whole Blood for Detecting Platelets in Lens-Free Images
  7. Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection
  8. CMPK2 and BCL-G are associated with type 1 interferon–induced HIV restriction in humans
  9. Impact of Point-of-Care Diagnostics on Clinical Decision-making in Low- and Middle-Income Countries
  10. Complex patterns of Hepatitis-C virus longitudinal clustering in a high-risk population
  11. Expanded cellular clones carrying replication-competent HIV-1 persist, wax, and wane
  12. Rapid and sensitive detection of viral nucleic acids using silicon microchips
  13. Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms
  14. New Therapies for Treating Hepatitis C Virus: Impact on Laboratory Testing Recommendations and Clinical Management
  15. Intracellular HIV-1 RNA and CD4+ T-cell activation in patients starting antiretrovirals
  16. It’s 10 pm ; Do You Know Where Your Data Are?
  17. Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance
  18. Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1
  19. Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles
  20. A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies
  21. Acute Hepatitis C Virus Infection Induces Consistent Changes in Circulating MicroRNAs That Are Associated with Nonlytic Hepatocyte Release
  22. Global Diversity within and between Human Herpesvirus 1 and 2 Glycoproteins
  23. Genome Sequencing and Analysis of Geographically Diverse Clinical Isolates of Herpes Simplex Virus 2
  24. CD4+T-Cell–Dependent Reduction in Hepatitis C Virus–Specific Neutralizing Antibody Responses After Coinfection With Human Immunodeficiency Virus
  25. Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance
  26. Inferring Viral Dynamics in Chronically HCV Infected Patients from the Spatial Distribution of Infected Hepatocytes
  27. Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study
  28. Accelerating Drug Development Through Collaboration: The Hepatitis C Drug Development Advisory Group
  29. Antiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus/hepatitis C virus coinfected patients
  30. Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses
  31. The Role of Viral Introductions in Sustaining Community-Based HIV Epidemics in Rural Uganda: Evidence from Spatial Clustering, Phylogenetics, and Egocentric Transmission Models
  32. Use of Laser Capture Microdissection to Map Hepatitis C Virus–Positive Hepatocytes in Human Liver
  33. Molecular epidemiology of GB type C virus among individuals exposed to hepatitis C virus in Cameroon
  34. Single Cell Laser Capture Microdissection Reveals the Hepatitis C Viral Landscape in the Human Liver
  35. Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents
  36. Constraints on Viral Evolution during Chronic Hepatitis C Virus Infection Arising from a Common-Source Exposure
  37. Laser captured hepatocytes show association of butyrylcholinesterase gene loss and fibrosis progression in hepatitis C-infected drug users
  38. Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution
  39. Immunogenicity and Cross-Reactivity of a Representative Ancestral Sequence in Hepatitis C Virus Infection
  40. Computational Reconstruction of Bole1a, a Representative Synthetic Hepatitis C Virus Subtype 1a Genome
  41. Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature
  42. Analysis of Genetic Linkage of HIV From Couples Enrolled in the HIV Prevention Trials Network 052 Trial
  43. The transhepatic endotoxin gradient is present despite liver cirrhosis and is attenuated after transjugular portosystemic shunt (TIPS).
  44. Molecular Epidemiology of HIV Type 1 in Singapore and Identification of Novel CRF01_AE/B Recombinant Forms
  45. A 61 year-old Female with a Prior History of Tuberculosis Presenting with Hemoptysis
  46. A 61-Year-Old Female with a Prior History of Tuberculosis Presenting with Hemoptysis
  47. Protective interleukin-28B genotype affects hepatitis C virus clearance, but does not contribute to HIV-1 control in a cohort of African–American elite controllers/suppressors
  48. Evolution of the HIV-1 nefgene in HLA-B*57 Positive Elite Suppressors
  49. Hepatitis C Virus Infection of Neuroepithelioma Cell Lines
  50. Analysis of HIV Diversity Using a High-Resolution Melting Assay
  51. Control of HIV-1 in Elite Suppressors despite Ongoing Replication and Evolution in Plasma Virus
  52. Acceleration of Hepatitis C Virus Envelope Evolution in Humans Is Consistent with Progressive Humoral Immune Selection during the Transition from Acute to Chronic Infection
  53. Genetic Linkage of Hepatitis B Virus in Peripheral Blood Leukocytes Provides Evidence for Contamination
  54. Spontaneous Control of Primary Hepatitis C Virus Infection and Immunity Against Persistent Reinfection
  55. Hepatitis C
  56. HIV‐1 Evolution Following Transmission to an HLA‐B*5801‐Positive Patient
  57. Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitution
  58. High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy
  59. Identification of Ongoing Human Immunodeficiency Virus Type 1 (HIV-1) Replication in Residual Viremia during Recombinant HIV-1 Poxvirus Immunizations in Patients with Clinically Undetectable Viral Loads on Durable Suppressive Highly Active Antiretrovir...
  60. Selection Pressure From Neutralizing Antibodies Drives Sequence Evolution During Acute Infection With Hepatitis C Virus
  61. Identification of Nevirapine‐Resistant HIV‐1 in the Latent Reservoir after Single‐Dose Nevirapine to Prevent Mother‐to‐Child Transmission of HIV‐1
  62. High-Programmed Death-1 Levels on Hepatitis C Virus-Specific T Cells during Acute Infection Are Associated with Viral Persistence and Require Preservation of Cognate Antigen during Chronic Infection
  63. Maternal Neutralizing Antibody and Transmission of Hepatitis C Virus to Infants
  64. Hepatitis C Virus Immune Escape via Exploitation of a Hole in the T Cell Repertoire
  65. Genetic Divergence of Hepatitis C Virus: The Role of HIV-Related Immunosuppression
  66. Human Immunodeficiency Virus-Related Microbial Translocation and Progression of Hepatitis C
  67. Acute hepatitis C
  68. Analyses of HIV-1 Drug-Resistance Profiles Among Infected Adolescents Experiencing Delayed Antiretroviral Treatment Switch After Initial Nonsuppressive Highly Active Antiretroviral Therapy
  69. Transmission of Human Immunodeficiency Virus Type 1 from a Patient Who Developed AIDS to an Elite Suppressor
  70. Comprehensive Genetic and Epigenetic Analysis of Occult Hepatitis B from Liver Tissue Samples
  71. CD4+T Cell Depletion in an Untreated HIV Type 1–Infected Human Leukocyte Antigen–B*5801–Positive Patient with an Undetectable Viral Load
  72. Early Archiving and Predominance of Nonnucleoside Reverse Transcriptase Inhibitor–Resistant HIV‐1 among Recently Infected Infants Born in the United States
  73. CD4 + T Cell–Dependent Reduction in Hepatitis C Virus–Specific Humoral Immune Responses after HIV Infection
  74. Slow Human Immunodeficiency Virus Type 1 Evolution in Viral Reservoirs in Infants Treated with Effective Antiretroviral Therapy
  75. Progression of Fibrosis during Chronic Hepatitis C Is Associated with Rapid Virus Evolution
  76. A sensitive genotyping assay for detection of drug resistance mutations in reverse transcriptase of HIV-1 subtypes B and C in samples stored as dried blood spots or frozen RNA extracts
  77. Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4+ T Cells
  78. Neutralizing Antibodies Do Not Mediate Suppression of Human Immunodeficiency Virus Type 1 in Elite Suppressors or Selection of Plasma Virus Variants in Patients on Highly Active Antiretroviral Therapy
  79. Humoral Immune Response in Acute Hepatitis C Virus Infection
  80. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C
  81. Cellular immune selection with hepatitis C virus persistence in humans
  82. Divergent and convergent evolution after a common-source outbreak of hepatitis C virus
  83. A Novel Assay Allows Genotyping of the Latent Reservoir for Human Immunodeficiency Virus Type 1 in the Resting CD4+ T Cells of Viremic Patients
  84. Prospective Evaluation of Community‐Acquired Acute‐Phase Hepatitis C Virus Infection
  85. Intermittent HIV-1 Viremia (Blips) and Drug Resistance in Patients Receiving HAART
  86. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF
  87. G→A Hypermutation in Protease and Reverse Transcriptase Regions of Human Immunodeficiency Virus Type 1 Residing in Resting CD4+ T Cells In Vivo
  88. Accurate Representation of the Hepatitis C Virus Quasispecies in 5.2-Kilobase Amplicons
  89. Genotypic Analysis of HIV‐1 Drug Resistance at the Limit of Detection: Virus Production without Evolution in Treated Adults with Undetectable HIV Loads
  90. Cross-Genotype Immunity to Hepatitis C Virus
  91. Continued Production of Drug-Sensitive Human Immunodeficiency Virus Type 1 in Children on Combination Antiretroviral Therapy Who Have Undetectable Viral Loads
  92. Characterization of novel recombinant HIV-1 genomes using the branching index
  93. Persistence of Wild-Type Virus and Lack of Temporal Structure in the Latent Reservoir for Human Immunodeficiency Virus Type 1 in Pediatric Patients with Extensive Antiretroviral Exposure
  94. Immunity against hepatitis C virus infection
  95. Needlestick Transmission of Hepatitis C
  96. Protection against persistence of hepatitis C
  97. Dynamics of SEN Virus Infection among Injection Drug Users
  98. Determinants of Viral Clearance and Persistence during Acute Hepatitis C Virus Infection
  99. Reorganization of genera in the families Rickettsiaceae and Anaplasmataceae in the order Rickettsiales: unification of some species of Ehrlichia with Anaplasma, Cowdria with Ehrlichia and Ehrlichia with Neorickettsia, descriptions of six new species co...
  100. HIV-1 Drug Resistance Profiles in Children and Adults With Viral Load of <50 Copies/mL Receiving Combination Therapy
  101. Human Immunodeficiency Virus Seroconversion and Evolution of the Hepatitis C Virus Quasispecies
  102. Prospective Characterization of Full-Length Hepatitis C Virus NS5A Quasispecies during Induction and Combination Antiviral Therapy
  103. Genetic Epidemiology of Hepatitis C Virus throughout Egypt
  104. A stable latent reservoir for HIV-1 in resting CD4+ T lymphocytes in infected children
  105. Hypervariable Region 1 Sequence Stability during Hepatitis C Virus Replication in Chimpanzees
  106. Determinants of the Quantity of Hepatitis C Virus RNA
  107. Sex and the genetic diversity of HIV-1
  108. Prevalence of Congenital Homocystinuria in Denmark
  109. Recrudescence of Treated Neurosyphilis in a Patient With Human Immunodeficiency Virus
  110. Autologous Strain-Specific Cytolytic T Lymphocyte Responses Directed against Human Immunodeficiency Virus Type 1 Env
  111. Characterization of a Polyclonal Cytolytic T Lymphocyte Response to Human Immunodeficiency Virus in Persons without Clinical Progression
  112. Ecchymoses and eschars at sites of injection
  113. Volatilization of mercury from natural water by a broad-spectrum Hg-resistantBacillus pasteurii strain DR2
  114. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: Prospective randomized comparison with parenteral therapy
  115. Predominance of defective proviral sequences in an HIV + long-term non-progressor
  116. Human Immunodeficiency Virus Type 1 env and p17gag Sequence Variation in Polymerase Chain Reaction-Positive, Seronegative Injection Drug Users
  117. Presence in India of HIV Type 1 Similar to North American Strains
  118. Eukaryotic start and stop translation sites
  119. Monomer sequence determination of carbohydrates using fast-atom bombardment mass spectrometry of periodate-oxidized acetate ester derivatives